New Delhi: Dr Reddy's Laboratories on Wednesday said it has launched Bortezomib for Injection, used to treat certain types of cancer, in the US market.
The Hyderabad-based drug major has launched the product after getting approval from the US Food and Drug Administration (USFDA).
The company's product is the generic version of Velcade brand.
According to IQVIA Health, Velcade and other generics have sales of around USD 1.2 billion in the US.
Dr Reddy's Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use, it noted.
/newsdrum-in/media/agency_attachments/ipXwqL5g8EOqSkmkiZUK.png)
/newsdrum-in/media/member_avatars/9Rj3p38eDEeibqzKtTLR.jpg )
Follow Us/newsdrum-in/media/post_banners/C7JdsHEMTBEoGA4spIKP.jpg)